Similar dietary regulation of IGF-1- and IGF-binding proteins by animal and plant protein in subjects with type 2 diabetes

Rita Schüler1,2 · Mariya Markova1,2 · Martin A. Osterhoff1,2,3 · Ayman Arafat3 · Olga Pivovarova1,2,3 · Jürgen Machann2,4,5 · Johannes Hierholzer6 · Silke Hornemann1 · Sascha Rohn7 · Andreas F. H. Pfeiffer8

Received: 6 November 2020 / Accepted: 16 February 2021 / Published online: 8 March 2021
© The Author(s) 2021

Abstract
Increased animal but not plant protein intake has been associated with increased mortality in epidemiological studies in humans and with reduced lifespan in animal species. Protein intake increases the activity of the IGF-1 system which may provide a link to reduced lifespan. We, therefore, compared the effects of animal versus plant protein intake on circulating levels of IGF-1 and the IGF-binding proteins (IGFBP)-1 and IGFBP-2 over a 6-week period. Thirty seven participants with type 2 diabetes consumed isocaloric diets composed of either 30% energy (EN) animal or plant protein, 30% EN fat and 40% EN carbohydrates for 6 weeks. The participants were clinically phenotyped before and at the end of the study. Both diets induced similar and significant increases of IGF-1 which was unaffected by the different amino acid compositions of plant and animal protein. Despite improvements of insulin sensitivity and major reductions of liver fat, IGFBP2 decreased with both diets while IGFBP-1 was not altered. We conclude that animal and plant protein similarly increase IGF-1 bioavailability while improving metabolic parameters and may be regarded as equivalent in this regard.

Keywords
Protein intake · Growth hormone · Insulin-like growth factor-1 · IGF-binding protein-1 · IGF-binding protein-2 · Plant protein · Animal protein

Introduction
The growth hormone/insulin-like growth factor-1 (IGF-1) system is highly interrelated with the insulin signaling pathway and function [1]. Reduced activation of insulin and IGF-1-pathways has been linked to longevity and a reduction of cancer, but it remains unclear whether this is linked to reduced IGF-1 pathway activity or to improved insulin sensitivity [2–5]. High protein intake increases circulating IGF-1 and reduces lifespan in C. elegans, flies and some strains of mice [2, 4]. A recent analysis of the NHANES III-study suggested that older people—in contrast to younger subjects—show improved survival with high protein intake suggesting an age-dependent response [6]. Moreover, plant protein intake in contrast to animal protein did not influence the association between protein intake and mortality [6]. In fact, epidemiological data suggest reduced mortality and cardiovascular events with higher plant protein intake [7]. The amino acid composition of protein therefore appears to determine responses [8], but it is not known, whether animal and plant proteins differ in their ability to increase IGF-1. Higher levels of IGF-1 were associated with improved...
muscle and bone mass [3, 9] and higher animal protein intakes were associated with reduced risks of osteoporotic fractures [10, 11]. Moreover, higher levels of IGF-1 may be associated with reduced risk of cardiovascular disease [12, 13]. Elevated levels of IGF-1 were linked to reduced risk of type 2 diabetes [14] in some studies while others observed neutral effects [3].

Less than 1% of circulating IGF-1 is free and thus bioactive. The bioactivity of IGF-1 is regulated by IGF-binding proteins (IGFBP). In particular IGFBP1 and IGFBP2 exert inhibitory actions on IGF-1 bioactivity and are strongly regulated by insulin and food intake [15–17]. A decrease of IGF-1 and an increase of IGFBP1 was moreover associated with increased risk of developing cardiac failure in older people with type 2 diabetes [18]. IGFBP-1 is acutely down-regulated by insulin and correlates closely with insulin sensitivity. Obese subjects and people with type 2 diabetes had lower levels of IGFBP1 and weight loss, as well as exercise increased levels of IGFBP1 [16, 17]. IGFBP2 was reported to correlate with increased intake of protein in epidemiological studies [19–21]. Humans with impaired glucose metabolism had reduced levels of IGFBP2 and IGFBP2 positively correlated with insulin sensitivity [16]. IGFBP2 moreover inhibited the differentiation of visceral but not subcutaneous adipocytes and was associated with a reduction of hepatic fat content in leptin-deficient mouse models [17].

The ideal amount and type of dietary protein intake is highly controversial at present due to its associations with life expectancy and disease risks in animal models and humans [2, 22]. We, therefore, evaluated the effects of animal versus plant protein-enriched diets (30% protein, 40% carbohydrates, 30% fat) in older patients with type 2 diabetes on circulating IGF-1, IGFBP1 and IGFBP2 levels. We particularly focused on the question whether animal and plant protein differentially alter the IGF-system in view of their different associations with disease risks which were proposed to be mediated by the IGF-system [2, 22]. We moreover assessed associations of changes of the IGF-system with changes of insulin sensitivity and anthropometry, particularly abdominal and subcutaneous fat mass, muscle mass and hepatic fat content in response to protein-rich diets.

Methods

LeguAn study

The LeguAn study protocol was approved by the ethics committee of the Charité-Universitätsmedizin Berlin and conducted in accordance with the principles of the Helsinki Declaration of 1975, as revised in 2000. All participants gave written informed consent prior to the study. A detailed description of the study design was published recently [23, 24]. The LeguAn study was registered with ClinicalTrials.gov: NCT02402985.

37 participants (24 males and 13 females) with type 2 diabetes (mean HbA1c 7.0 ± 0.1%) and a mean age of 64 ± 1 years were randomized according to weight, age, sex, HbA1c and medication as described in detail [25] and received an isocaloric high-protein diet (30% protein, 40% carbohydrates and 30% fat) for 6 weeks. Blood samples were collected after an overnight fast before and after the high-protein dietary intervention.

Serum concentrations of IGF-1 and IGFBPs

Concentrations of serum IGF-1, IGFBP1 and IGFBP2 were measured using ELISA (Mediagnost, Reutlingen, Germany).

Statistical analysis

Variables were tested for normal distribution using the Kolmogorov–Smirnov test. One-way or repeated measures ANOVA followed by Bonferroni post hoc test was used for statistical comparison of mean values of continuous data. Pearson’s and Spearman’s rank correlation coefficients were used for correlation analysis for variables with normal and skewed distribution, respectively. Unless otherwise stated data are reported as mean ± SEM. Statistical significance level was designated at P < 0.05. Statistical analysis was performed using SPSS 20.0 (IBM, Chicago, IL, USA).

Results

A total of 37 overweight to moderately obese subjects with T2DM completed the study. Patients were on average 64 years old and under oral antidiabetic treatment with HbA1c values of 7%. At baseline, the participants consumed diets which contained 42% carbohydrates, 17% protein and 41% fat. They were randomized to receive either an animal protein (AP) rich or a plant protein (PP)-rich diet. During the intervention, the protein intake was increased to 30% of energy intake and exchanged against fat intake in both groups as previously described in detail [23, 24]. The diets were partly supplied and the protein intake was monitored by determination of urea in the blood and urine which increased by about 30%. The plant protein diets contained pea protein-enriched noodles, bread and a pea mash to achieve the high plant protein intake over 6 weeks. The amino acid composition of the nutrition was calculated from dietary protocols [25] and plasma levels were determined after representative meals [26] which showed higher concentrations of the branched chain amino acids, tryptophane and methionine in the animal protein group while asparagine and arginine were
higher in plant protein group. Fasting levels of amino acids did not differ between the diets [23].

The high-protein diet induced a highly significant increase in IGF-1 by about 14% overall (Table 1). Quite unexpectedly this increase was seen in both groups, i.e. with high plant protein and with high animal protein without significant differences between the groups ($p = 0.639$, Table 2).

IGFBP1 concentrations did not change with the diets neither overall nor in the AP and PP groups, respectively ($p = 0.361$, $p = 0.215$ and $p = 0.968$). In contrast, IGFBP2 levels decreased significantly overall by 12% (Table 1). Stratified by the protein source, this decrease was not significant neither in the AP nor in the PP group although a similar tendency was observed in both groups.

IGF-1 levels significantly correlated with IGFBP2 levels at baseline ($\rho = 0.456$, $p = 0.005$). IGFBP1 and IGFBP2 levels were significantly correlated before and after the high-protein diet ($\rho = 0.369$, $p = 0.025$ and $\rho = 0.435$, $p = 0.007$). Baseline levels of IGF-1 modestly negatively correlated with BMI but not with other anthropometric parameters. Furthermore, IGF-1 was strongly negatively correlated with hepatic fat content determined by MRI spectroscopy before and after the high-protein diet (Table 3). IGFBP1 showed highly negative correlations with anthropometric measures including BMI, waist circumference and WHR and moderate negative correlations with fasting insulin and insulin sensitivity as determined by HOMA. IGFBP2 was highly negatively correlated with fasting insulin and HOMA and with hepatic fat content in addition to BMI and waist circumference (Table 3).

The highly negative correlation of IGF-1 and of IGFBP2 with the hepatic fat content was preserved despite a reduction of hepatic fat content by 47% after 6 weeks of high-protein diet. Similarly, the correlation of IGFBP1 and IGFBP2 with insulin sensitivity and anthropometric variables became somewhat stronger after 6 weeks (Table 3).

Table 1 Effects of HP diet on IGF-1 and IGFBPs concentrations

|          | Glucose (mmol/l) | Insulin (mU/l) | HOMA-IR | IGF-1 (µg/l) | IGFBP-1 (µg/l) | IGFBP-2 (µg/l) |
|----------|------------------|----------------|----------|--------------|----------------|----------------|
| 0 weeks  | 9.56 ± 1.64      | 9.39 ± 6.43    | 4.08 ± 3.07 | 183.6 ± 8.2  | 5.5 ± 0.6       | 260.3 ± 25.0   |
| 6 weeks  | 8.99 ± 1.90      | 8.73 ± 6.49    | 3.42 ± 2.38 | 209.2 ± 7.8  | 5.5 ± 1.0       | 228.2 ± 17.8   |

Values are shown as mean ± SD. (Wilcoxon)

Table 2 Effects of HP diet on IGF-1 and IGFBPs concentrations stratified by protein source

|          | AP              | PP              |          |              |              |              |
|----------|-----------------|-----------------|----------|--------------|----------------|----------------|
| Glucose (mmol/l) | 9.64 ± 1.81 | 9.48 ± 1.49     | 9.81 ± 1.51 | 9.35 ± 2.19  | 0.006           | 0.039           |
| Insulin (mU/l)   | 10.07 ± 7.18    | 8.74 ± 5.75     | 8.31 ± 5.40 | 9.12 ± 7.50  | 0.109           | 0.536           |
| HOMA-IR          | 4.45 ± 3.71     | 3.71 ± 2.33     | 3.15 ± 2.09 | 3.67 ± 2.65  | 0.117           | 0.651           |
| IGF-1 (µg/l)     | 183.3 ± 13.0    | 183.8 ± 10.5    | 210.8 ± 12.6 | 207.7 ± 9.7  | 0.078           | 0.117           |
| IGFBP-1 (µg/l)   | 5.3 ± 0.9       | 5.7 ± 0.9       | 4.8 ± 1.3  | 4.8 ± 1.3    | 0.215           | 0.968           |
| IGFBP-2 (µg/l)   | 229.8 ± 26.7    | 289.1 ± 41.3    | 206.7 ± 20.6 | 248.5 ± 28.4 | 0.006           | 0.039           |

Table 3 Correlation analysis of IGF-1 and IGFBPs with anthropometric and biochemical parameters before and after high-protein diet

|          | BMI        | Waist | WHR | VAT(l) | IHL | Insulin | HOMA-IR |
|----------|------------|-------|-----|--------|-----|---------|---------|
| IGF-1    |            |       |     |        |     |         |         |
| 0 weeks  | −0.345*    |       |     | −0.530** |     |         |         |
| 6 weeks  |            |       |     | −0.587*** |    |         |         |
| IGFBP1   |            |       |     | −0.564*** | −0.502** | −0.358* | −0.348* |
| 0 weeks  | −0.437**   |       |     | −0.427** | −0.578*** | −0.520** | −0.496** |
| 6 weeks  |            |       |     | −0.570*** | −0.542*** | −0.548** | −0.579*** |
| IGFBP2   |            |       |     |        |     |         |         |
| 0 weeks  | −0.598***  |       |     | −0.501** | −0.413* | −0.620*** | −0.707*** |
| 6 weeks  |            |       |     | −0.576*** | −0.542*** |         |         |

Correlation of IGF-1 and IGFBPs with anthropometric measures and metabolic parameters. Only significant correlations (Spearman’s rank correlation coefficients) are presented

* $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$
In the LEGUAN study, we addressed the question whether the protein source in a high-protein diet, animal- vs. plant-based protein, is a relevant determinant of circulating IGF-1, IGFBP1 and 2 levels in participants with type 2 diabetes.

The most striking finding is that plant protein induces similar increases of IGF-1 as animal protein does. In view of the associations of PP with reductions in overall and cardiovascular mortality as compared to AP this is highly relevant [7]. It provides an argument against a role of IGF-1 in mediating the negative effects of high animal protein intake. Indeed the literature on this topic is rather inconclusive at present [27]. Accordingly, our results suggest that differences between plant vs. animal protein intake and cancer or cardiovascular risk do not arise from their effects on components of the IGF-1-system but protective properties of other components present in plant-based diets. Notably, most epidemiological studies do not account for confounding due to differences in lifestyle of meat consumers versus vegetarians. Recent large population-based cohort studies extensively correcting for confounding did not find differences in mortality between vegetarians and non-vegetarians [28, 29].

Vegan diet was associated with lower IGF-1 and higher IGFBP1 and IGFBP2 levels in cross-sectional studies compared to vegetarian and meat-containing diets. Low levels of IGF-1 were associated with increased risk for angiographically confirmed coronary heart disease in cross-sectional [30] and prospective studies [31] and predicted death thereafter [32]. This may be explained by the rather potent effects of IGF-1 on cardiac remodeling and endothelial as well as smooth muscle cells [33, 34]. IGF-1 prevents age-related decreases in cardiomyocyte number, decreased synthesis of contractile proteins and fibrosis [35]. Therefore, changes induced by low-protein diets in these components of the IGF-system appear to be unfavorable and outcomes from studies in short-lived animals which are little affected by cardiovascular disease should not be translated to humans.

A further unexpected finding of our study was that IGFBP2 levels decreased upon high protein intake. Elevated levels of IGFBP2 were associated with death from ischemic heart disease [36] and were also a biomarker of increased mortality in elderly subjects [37]. On the other hand, IGFBP2 decreased liver fat and improved metabolic markers upon overexpression in mice [38] and was associated with a more favorable metabolic profile in humans [37]. We observed similar inverse associations of IGFBP2 with visceral adipose tissue, liver fat and insulin levels and insulin sensitivity in our study. In fact, the inverse associations with visceral adipose tissue and liver fat became much more pronounced after 6 weeks of high-protein diet, despite the decrease of IGFBP2 (Table 3). We therefore interpret the reduction of IGFBP2 as an advantage which will enhance the increase of bioactive IGF-1 particularly in the extravascular compartment [27].

The observation that IGFBP1 was not altered is noteworthy since increases of IGFBP-1 were reported to associate with the beneficial effects of protein restriction in animal studies. In humans, increased levels of IGFBP-1 not only predicted heart failure in a prospective study after myocardial infarction but also overall mortality over 8 years [39]. IGFBP1 was also elevated in patients with severe coronary heart disease in people with [40] and without [41] type 2 diabetes. IGFBP1 is strongly regulated by insulin and decreased in subjects with insulin resistance [16] and was inversely correlated with insulin levels, waist circumference and abdominal fat content in this study [40].

It has been postulated that dietary intake of essential amino acids is a determining factor of IGF-1 levels. Allen and coworkers postulated that the lower intake of protein in high in essential amino acids may account for the difference in IGF-1 and IGFBP concentrations between diets [42]. However, these studies were cross-sectional. Plant protein differed in our study from the animal protein by a lower content of leucine and methionine and a higher content of arginine and asparagine. These intakes altered postprandial amino acid driven-specific hormonal responses as recently previously reported [26]. Since both diets had similar effects on IGF-1 and IGFBP1 and 2, our data do not support an important effect of the protein composition but rather suggest that the amount of protein determines the response in case of high-protein diets. This may, however, not apply to low-protein diets were the differences in amino acid composition may lead to specific deficiencies and thereby induce amino acid driven-specific hormonal responses as recently reported for FGF21 and IGF-1 [43]. Nevertheless, levels of IGF-1 were primarily related to the nitrogen balance and less to deficiency of specific amino acids.

In summary, our data show that animal and plant proteins exert similar effects on IGF-1, IGFBP2 and 3. The increases in IGF-1 and moderate decreases in IGFBP2 are likely to exert positive effects on cardiovascular and bone health and were associated with significant improvements of metabolic risk markers such as liver fat content, insulin sensitivity and visceral and subcutaneous fat content. Therefore, the current study provides arguments for an increased protein intake in the context of a healthy diet regarding fat and plant food intake in participants with type 2 diabetes and an age above 60 years.

Acknowledgements The study was funded by a grant from the German Federal Ministry of Food and Agriculture (BLE, Grant No.
2815407110). We thank Katrin Ritter, Andrea Borchert and Tanja Ahrens for excellent technical assistance.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Compliance with ethical standards**

**Conflict of interest** None of the authors reports any conflicts of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Russell SJ, Kahn CR (2007) Endocrine regulation of ageing. Nat Rev Mol Cell Biol 8(9):681–691. https://doi.org/10.1038/nrm2234

2. LongoVD, Antebi A, Bartke A, Barzilai N, Brown-Borg HM, Caruso C, Curriel TJ, de Cabo R, Franceschi C, Gems D, Ingram DK, Johnson TE, Kennedy BK, Kenyon C, Klein S, Kopchik JJ, Lepperdinger G, Madeo F, Mirisola MG, Mitchell JR, Passarino G, Rudolph KL, Sedivy JM, Shadel GS, Sinclair DA, Spindler SR, Suh Y, Vigg J, Vinciguerra M, Fontana L (2015) Interventions to slow aging in humans: are we ready? Aging Cell 14(4):497–510. https://doi.org/10.1111/ace.12338

3. MilmanS,uffman DM, Barzilai N (2016) The somatotropic axis in human aging: framework for the current state of knowledge and future research. Cell Metab 23(6):980–989. https://doi.org/10.1016/j.cmet.2016.05.014

4. Mirrazei H, Suarez JA, Longo VD (2014) Protein and amino acid restriction, aging and disease: from yeast to humans. Trends Endocrinol Metab 25(11):558–566. https://doi.org/10.1016/j.tem.2014.07.002

5. Novosyadlyr R, Leroith D (2012) Insulin-like growth factors and insulin: at the crossroad between tumor development and longevity. J Gerontol A Biol Sci Med Sci 67(6):640–651. https://doi.org/10.1093/gerona/gls065

6. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, Passarino G, Kennedy BK, Wei M, Cohen P, Crimmings EM, Longo VD (2014) Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 19(3):407–417. https://doi.org/10.1016/j.cmet.2014.02.006S1550-4131(14)000062 -X[pii]

7. Song M, Fung TT, Hu FB, Willett WC, Longo VD, Chan AT, Giovannucci EL (2016) Association of animal and plant protein intake with all-cause and cause-specific mortality. JAMA Intern Med 176(10):1453–1463. https://doi.org/10.1001/jamainternmed.2016.4182

8. Piper MDW, Soutoukis GA, Blanc E, Mesaros A, Herbert SL, Juricic P, He X, Atanassov I, Salmonowicz H, Yang M, Simpson SJ, Ribeiro C, Partridge L (2017) Matching dietary amino acid balance to the in-silico-translated exome optimizes growth and reproduction without cost to lifespan. Cell Metab 25(5):1206. https://doi.org/10.1016/j.cmet.2017.04.020

9. Clemons DR (2009) Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab 20(7):349–356. https://doi.org/10.1016/j.tem.2009.04.002

10. Langsetmo L, Shikany JM, Cawthon PM, Cauley JA, Taylor BC, Vo TN, Bauer DC, Orwoll ES, Schoubsje JT, Ensrud KE, Osteoporotic Fractures in Men Research G (2017) The association between protein intake by source and osteoporotic fracture in older men: a prospective cohort study. J Bone Miner Res 32(3):592–600. https://doi.org/10.1002/jbmr.3058

11. Sahni S, Cupples LA, McLean RR, Tucker KL, Broe KE, Kiel DP, Hannan MT (2010) Protective effect of high protein and calcium intake on the risk of hip fracture in the Framingham offspring cohort. J Bone Miner Res 25(12):2770–2776. https://doi.org/10.1002/jbmr.194

12. Li Y, Shelat H, Wu H, Zhu M, Xu J, Geng YJ (2014) Low circulating level of IGF-1 is a distinct indicator for the development of cardiovascular disease caused by combined hyperglycemia and dyslipidemia. Int J Cardiol 171(2):272–273. https://doi.org/10.1016/j.ijcard.2013.11.091

13. Akanji AO, Smith RJ (2012) The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr Relat Disord 10(1):3–13. https://doi.org/10.1089/met.2011.0083

14. Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosset J, Hu FB, Strickler HD (2012) Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes 61(9):2248–2254. https://doi.org/10.2337/db11-1488

15. Maddux BA, Chan A, De Filippis EA, Mandarinjo LJ, Goldfine ID (2006) IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 29(7):1535–1537

16. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schoff C, Mohlig M, Pfeiffer AF (2009) The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-1 bioactivity. J Clin Endocrinol Metab 94(12):5093–5101

17. Clemons DR (2016) Role of IGF binding proteins in regulating metabolism. Trends Endocrinol Metab 27(6):375–391. https://doi.org/10.1016/j.tem.2016.03.019

18. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL (2005) Insulin-like growth factors and coronary heart disease. Circ Rev 13(1):35–39. https://doi.org/10.1097/01.crd.0000134914.10407.40

19. Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad K, Gronbaek H, Tjonneland A, Halkjaer J, Dossus L, Boeing H, Kroger J, Trichopoulos A, Dilsiv V, Trichopoulos D, Boutron-Ruault MC, De Launoz B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Timino R, Sacerdote C, Bruno-de-Mesquita HB, Vrieling A, van Gils CH, Peeters PH, Gram IT, Skeie G, Lund E, Rodriguez L, Jakxyn P, Molina-Montes E, Tormo MJ, Barricarte A, Lagarrana N, Khaw KT, Bingham S, Rinaldi S, Slimani N, Norat T, Gallor V, Riboli E, Kaaks R (2009) The association between diet and serum concentrations of IGF-1, IGFBP-1, IGFBP-2, and IGFBP-3 in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 18(5):1333–1340. https://doi.org/10.1158/1055-9965.EPI-08-0781

20. Hoeftich A, Wirthgen E, David R, Classen CF, Spitschak M, Brenmoel J (2014) Control of IGFBP-2 expression by steroids and peptide hormones in vertebrates. Front Endocrinol (Lausanne) 5:43. https://doi.org/10.3389/fendo.2014.00043
